Renaissance Technologies LLC Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Renaissance Technologies LLC increased its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 7.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,706,116 shares of the biopharmaceutical company's stock after purchasing an additional 180,100 shares during the quarter. Renaissance Technologies LLC owned approximately 2.27% of Catalyst Pharmaceuticals worth $56,477,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in shares of Catalyst Pharmaceuticals by 4.9% in the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock valued at $175,957,000 after buying an additional 390,116 shares in the last quarter. Pacer Advisors Inc. boosted its stake in Catalyst Pharmaceuticals by 5.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company's stock valued at $61,681,000 after acquiring an additional 151,495 shares in the last quarter. Boston Partners grew its holdings in shares of Catalyst Pharmaceuticals by 1.3% during the fourth quarter. Boston Partners now owns 1,291,868 shares of the biopharmaceutical company's stock worth $27,325,000 after purchasing an additional 16,601 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Catalyst Pharmaceuticals by 6.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company's stock worth $26,023,000 after purchasing an additional 79,182 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Catalyst Pharmaceuticals by 80.3% in the 4th quarter. JPMorgan Chase & Co. now owns 736,197 shares of the biopharmaceutical company's stock valued at $15,364,000 after purchasing an additional 327,936 shares during the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Catalyst Pharmaceuticals Trading Up 1.1 %

Shares of CPRX traded up $0.25 during trading hours on Tuesday, reaching $23.05. The company had a trading volume of 278,494 shares, compared to its average volume of 1,139,861. The company has a market capitalization of $2.80 billion, a price-to-earnings ratio of 19.53, a PEG ratio of 3.31 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.47 and a 12-month high of $26.16. The firm has a 50 day simple moving average of $22.62 and a 200-day simple moving average of $22.04.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Bank of America restated a "buy" rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Stephens reaffirmed an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Finally, Robert W. Baird upped their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Catalyst Pharmaceuticals currently has an average rating of "Buy" and an average price target of $32.29.

Insider Activity

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Gary Ingenito sold 44,904 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now directly owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.00% of the company's stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.